Key Advances in Precision Medicine in Lung Cancer
Robert Coleman, MD, FACOG, FACS, discusses key advances in precision medicine in lung cancer.
Robert Coleman, MD, FACOG, FACS the chief scientific officer for US Oncology Research, supported by McKesson, and an oncologist with Texas Oncology, discusses key advances in precision medicine in lung cancer.
According to Coleman, lung cancer has been the “poster child” for precision medicine in recent months. Recent approvals have expanded targetable molecular alterations, such as EGFR mutations. More emphases have been placed on such targets, even though they make up a small picture of the overall lung cancer space.
Treatment for these molecular anomalies have been moved to earlier lines of treatments. Many approvals for these mutations exist in other cancer types, according to Coleman. Immunotherapy, both as a monotherapy and in combination, for other mutations such as RAS, MET, and, RET have also been moved to earlier therapy lines.
Biomarker Testing Paves the Way for Better Targeted Therapies in NSCLC
April 16th 2024At a live virtual event, Edward S. Kim, MD, MBA, discussed the evolving landscape of biomarker testing before making treatment decisions for patients with early-stage non–small cell lung cancer (NSCLC).
Read More
Multiple Resistance Mechanisms Thwart Efficacy for Third-Generation TKIs in NSCLC
April 7th 2024An important clinical strategy that focuses on improved frontline EGFR TKI regimens may help combat acquired EGFR TKI resistance and further streamline treatment options in subsequent lines, according to Balazs Halmos, MD.
Read More
Repotrectinib Elicits an Intracranial Response in ROS1+ Advanced NSCLC
April 5th 2024During a Case-Based Roundtable® event, Christine Bestvina, MD, discussed the intracranial responses to repotrectinib for patients with ROS1-psotive non-small cell lung cancer in the first article of a 2-part series.
Read More
